Our Blog

Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty pharmacies continue to dominate the dispensing of specialty drugs. For 2025, DCI has identified more...

PANTHERx Rare’s CEO, Bansi Nagji, authored an insightful guest post for Drug Channels Institute titled, “The Rare Journey Needs a Special Pharmacy Partner.” He makes...

Next week, the Drug Channels Institute (DCI) will release our 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. This 17th edition provides our most...

Communication gaps, preventable delays and limited support place significant responsibility on patients on the rare disease journey, a new survey finds. The survey (PDF) was...

In this Drug Channels Institute guest post, “Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different,” PANTHERx’s Chief Commercial & Clinical Officer, Dr. Richard...

Dr. Richard Faris, our Chief Commercial and Clinical Officer, recently submitted a proposal on behalf of PANTHERx in response to the FDA’s request for public...

Dr. Richard Faris, PhD, MSc, RPh, will bring his extensive expertise to NASP, helping to guide the organization as it advances specialty pharmacy, promotes innovation,...

Bansi explores how the emerging model of “Rare Pharmacy” addresses the challenges rare diseases pose to patients, caregivers, and the healthcare system. His perspective highlights...

Dr. Richard Faris outlines the key factors for commercialization success when a manufacturer launches treatments for rare and orphan diseases. He explains the key considerations...

PANTHERx Rare Pharmacy is proud to have again earned the #1 ranking in the quarterly patient satisfaction survey conducted by MMIT, an independent national survey entity....